- Home
- VVV vs PTCT Comparison
VVV vs PTCT Comparison
Compare VVV & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- PTCT
- Stock Information
- Founded
- VVV 1866
- PTCT 1998
- Country
- VVV United States
- PTCT United States
- Employees
- VVV N/A
- PTCT N/A
- Industry
- VVV Major Chemicals
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- PTCT Health Care
- Exchange
- VVV Nasdaq
- PTCT Nasdaq
- Market Cap
- VVV 5.0B
- PTCT 4.1B
- IPO Year
- VVV 2016
- PTCT 2013
- Fundamental
- Price
- VVV $40.67
- PTCT $59.69
- Analyst Decision
- VVV Buy
- PTCT Buy
- Analyst Count
- VVV 12
- PTCT 14
- Target Price
- VVV $43.00
- PTCT $67.00
- AVG Volume (30 Days)
- VVV 1.4M
- PTCT 1.3M
- Earning Date
- VVV 08-06-2025
- PTCT 11-06-2025
- Dividend Yield
- VVV N/A
- PTCT N/A
- EPS Growth
- VVV 68.45
- PTCT N/A
- EPS
- VVV 2.14
- PTCT 7.72
- Revenue
- VVV $1,692,000,000.00
- PTCT $1,764,929,000.00
- Revenue This Year
- VVV $6.86
- PTCT $119.89
- Revenue Next Year
- VVV $14.28
- PTCT N/A
- P/E Ratio
- VVV $18.94
- PTCT $7.64
- Revenue Growth
- VVV 7.53
- PTCT 96.00
- 52 Week Low
- VVV $31.02
- PTCT $33.58
- 52 Week High
- VVV $43.74
- PTCT $62.18
- Technical
- Relative Strength Index (RSI)
- VVV 52.67
- PTCT 67.56
- Support Level
- VVV N/A
- PTCT $58.87
- Resistance Level
- VVV $40.68
- PTCT $62.18
- Average True Range (ATR)
- VVV 0.73
- PTCT 2.10
- MACD
- VVV -1.39
- PTCT 0.60
- Stochastic Oscillator
- VVV 99.89
- PTCT 81.31
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.